Skip to main content
. Author manuscript; available in PMC: 2017 Dec 7.
Published in final edited form as: Clin Cancer Res. 2017 Feb 7;23(14):3684–3691. doi: 10.1158/1078-0432.CCR-16-1859

Figure 1.

Figure 1

Flow diagram of patient recruitment in ACRIN 6695. Eligible: target lesion met target lesion criteria on central review; Evaluable: patient with technically analyzable CTP scans of the same target lesion from T0 and T2; Suboptimal: Suboptimally debulked tumor; Dose-dense: weekly paclitaxel; Conventional: 3-weekly paclitaxel; Bev =Bevacizumab